Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avalyn Pharma Inc. Common Stock
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Active, not recruiting
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
AP01
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis +8
NCT06329401Enrollment398StartApr 2024Primary CompletionJun 2027est.CompletionJun 2027est. - Phase 2Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
AP01
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
NCT06951217Enrollment340StartApr 2025Primary CompletionDec 2031est.CompletionDec 2031est. - Phase 2Recruiting
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
AP02, Placebo
Idiopathic Pulmonary Fibrosis (IPF)
NCT07194382Enrollment160StartMar 2026Primary CompletionDec 2026est.CompletionJun 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Active, not recruiting | AP01 | NCT06329401 |
| Phase 2 | Recruiting | AP01 | NCT06951217 |
| Phase 2 | Recruiting | AP02, Placebo | NCT07194382 |